Amphastar Pharmaceuticals, Inc.

NasdaqGS:AMPH 株式レポート

時価総額:US$2.5b

Amphastar Pharmaceuticals マネジメント

マネジメント 基準チェック /44

Amphastar Pharmaceuticalsの CEO はJack Zhangで、 Jan1996年に任命され、 の在任期間は 28.83年です。 の年間総報酬は$ 7.72Mで、 11.6%給与と88.4%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の5.01%を直接所有しており、その価値は$ 125.70M 。経営陣と取締役会の平均在任期間はそれぞれ11年と5.4年です。

主要情報

Jack Zhang

最高経営責任者

US$7.7m

報酬総額

CEO給与比率11.6%
CEO在任期間28.8yrs
CEOの所有権5.0%
経営陣の平均在職期間11yrs
取締役会の平均在任期間5.4yrs

経営陣の近況

Recent updates

Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)

Oct 25

Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Sep 15
Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines

Sep 12

Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?

Aug 27
Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?

Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Jul 05
Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming

Jul 01

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity

May 30
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity

Amphastar Pharmaceuticals: Buy When Fear Is Overblown

May 30

Reassessing Amphastar Pharmaceuticals

May 15

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet

Mar 27
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet

Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions

Mar 04

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Jan 04
Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E

Dec 20
Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet

Dec 03
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet

Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth

Sep 18
Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth

An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued

Sep 03
An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Aug 17
These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching

Jun 02
Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

May 11
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price

Mar 02
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price

Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?

Feb 07
Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?

Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?

Jan 24
Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?

Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors

Nov 02
Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors

Amphastar: A Pharmaceutical Growth Stock

Oct 06

Amphastar wins FDA approval for Epinephrine pre-filled syringes

Aug 16

Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond

Aug 08

Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Jul 24
Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Amphastar generic vasopressin for increasing blood pressure gets FDA approval

Jul 19

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

Jun 10
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

CEO報酬分析

Amphastar Pharmaceuticals の収益と比較して、Jack Zhang の報酬はどのように変化したか?
日付総報酬給与会社業績
Jun 30 2024n/an/a

US$167m

Mar 31 2024n/an/a

US$155m

Dec 31 2023US$8mUS$898k

US$138m

Sep 30 2023n/an/a

US$135m

Jun 30 2023n/an/a

US$102m

Mar 31 2023n/an/a

US$93m

Dec 31 2022US$7mUS$1m

US$91m

Sep 30 2022n/an/a

US$77m

Jun 30 2022n/an/a

US$91m

Mar 31 2022n/an/a

US$81m

Dec 31 2021US$7mUS$898k

US$62m

Sep 30 2021n/an/a

US$36m

Jun 30 2021n/an/a

US$10m

Mar 31 2021n/an/a

US$2m

Dec 31 2020US$6mUS$898k

US$1m

Sep 30 2020n/an/a

US$7m

Jun 30 2020n/an/a

US$4m

Mar 31 2020n/an/a

US$52m

Dec 31 2019US$6mUS$898k

US$49m

Sep 30 2019n/an/a

US$52m

Jun 30 2019n/an/a

US$53m

Mar 31 2019n/an/a

US$2m

Dec 31 2018US$6mUS$1m

-US$6m

Sep 30 2018n/an/a

-US$7m

Jun 30 2018n/an/a

-US$9m

Mar 31 2018n/an/a

-US$4m

Dec 31 2017US$6mUS$880k

US$4m

報酬と市場: Jackの 総報酬 ($USD 7.72M ) は、 US市場 ($USD 6.64M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Jackの報酬は、過去 1 年間の会社の業績と一致しています。


CEO(最高経営責任者

Jack Zhang (77 yo)

28.8yrs

在職期間

US$7,722,768

報酬

Dr. Yongfeng Zhang, also known as Jack, Ph D., has been President at Amphastar Pharmaceuticals, Inc. since April 10, 2020. He co-founded Amphastar Pharmaceuticals in 1996 and has been its Chief Executive O...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Ziping Luo
Chairman of the Board28.8yrsUS$3.77m2.36%
$ 59.1m
Yongfeng Zhang
Co-founder28.8yrsUS$7.72m5.01%
$ 125.7m
William Peters
CFO, Executive VP of Finance10.6yrsUS$2.89m0.075%
$ 1.9m
Jacob Liawatidewi
Executive VP of Sales11.4yrsUS$1.78m0.096%
$ 2.4m
Rong Zhou
Senior EVP of Production & EVP of Scientific Affairs9.4yrsUS$2.03m0.38%
$ 9.6m
Dan Dischner
Senior Vice President of Human Resources & Corporate Communication2.3yrsデータなしデータなし
Tony Marrs
Executive VP of Regulatory Affairs & Clinical Operationsno dataデータなしデータなし

11.0yrs

平均在職期間

65yo

平均年齢

経験豊富な経営陣: AMPHの経営陣は経験豊富で経験豊富です(平均在職期間は11年)。


取締役

名称ポジション在職期間報酬所有権
Ziping Luo
Chairman of the Board28.8yrsUS$3.77m2.36%
$ 59.1m
Yongfeng Zhang
Co-founder28.8yrsUS$7.72m5.01%
$ 125.7m
William Peters
CFO, Executive VP of Finance2.3yrsUS$2.89m0.075%
$ 1.9m
Jacob Liawatidewi
Executive VP of Sales2.3yrsUS$1.78m0.096%
$ 2.4m
Richard Prins
Lead Independent Director22.8yrsUS$362.00k0.063%
$ 1.6m
Gayle Deflin
Independent Director3.4yrsUS$330.00k0%
$ 0
Chen Yang
Member of Scientific Advisory Boardno dataデータなしデータなし
Paul White
Member of Scientific Advisory Boardno dataデータなしデータなし
Gordon Treweek
Member of Scientific Advisory Boardno dataデータなしデータなし
Herschel Rabitz
Member of Scientific Advisory Boardno dataデータなしデータなし
Richard Porter
Member of Scientific Advisory Boardno dataデータなしデータなし
Diane Gerst
Independent Director5.4yrsUS$314.70k0.026%
$ 662.1k

5.4yrs

平均在職期間

65.5yo

平均年齢

経験豊富なボード: AMPHの 取締役会経験豊富 であると考えられます ( 5.4年の平均在任期間)。